Ampio Pharmaceuticals Inc (AMPE) Short Interest Update

Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the recipient of a significant increase in short interest in the month of December. As of December 29th, there was short interest totalling 9,749,519 shares, an increase of 9.6% from the December 15th total of 8,894,839 shares. Based on an average trading volume of 2,362,490 shares, the short-interest ratio is presently 4.1 days. Currently, 14.2% of the shares of the company are sold short.

Ampio Pharmaceuticals (NYSEAMERICAN AMPE) opened at $2.93 on Friday. The stock has a market capitalization of $190.19, a P/E ratio of -14.65 and a beta of 0.51. Ampio Pharmaceuticals has a 1 year low of $0.38 and a 1 year high of $4.95.

Separately, ValuEngine upgraded Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 11th.

ILLEGAL ACTIVITY WARNING: “Ampio Pharmaceuticals Inc (AMPE) Short Interest Update” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/13/ampio-pharmaceuticals-inc-ampe-short-interest-update.html.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit